Ignite Creation Date:
2025-12-24 @ 4:12 PM
Ignite Modification Date:
2026-03-26 @ 4:07 PM
Study NCT ID:
NCT01663766
Status:
TERMINATED
Last Update Posted:
2021-08-19
First Post:
2012-08-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Study of Milatuzumab for Graft Versus Host Disease
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-12
Start Date Type:
ACTUAL
Primary Completion Date:
2015-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-03
Completion Date Type:
ACTUAL
First Submit Date:
2012-08-07
First Submit QC Date:
None
Study First Post Date:
2012-08-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-08-12
Last Update Post Date:
2021-08-19
Last Update Post Date Type:
ACTUAL